The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study

Thrombosis and Haemostasis

Volumn 93, Issue 1, 2005, Pages 92-96

  van Goor, Mary Lou P J ^a   García, Encarna Gómez ^a   Leebeek, Frank ^a   Brouwers, Geert Jan ^a   Koudstaal, Peter ^a   Dippel, Diederik ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Case control; Ischemic stroke; PAI 1 4G 5G polymorphism; PAI 1 level

Indexed keywords

GUANINE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ACCURACY; ADULT; AGE DISTRIBUTION; AGED; ALLELE; ANAMNESIS; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CAUCASIAN; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GREAT BLOOD VESSEL; HEART DISEASE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; RISK ASSESSMENT; SCREENING TEST; SEX DIFFERENCE; VALIDATION PROCESS; VENOUS BLOOD;

ADULT; AGED; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES;

EID: 12344303488     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-09-0560     Document Type: Article

References (25)

1. Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude Cas Temoins de I'nfarctus du Myocarde. Thromb Haemost 1995; 74: 837-41.
2. Catto AJ, Carter AM, Stickland M, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997; 77: 730-4.
3. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
4. Ny T, Sawdey M, Lawrence D, et al. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A 1986; 83: 6776-80.
5. Wiman B, Chmielewska J, Ranby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-7.
6. Strandberg L, Lawrence D, Ny T. The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. Eur J Biochem 1988; 176: 609-16.
7. Dawson S, Hamsten A, Wiman B, et al. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-90.
8. Boekholdt SM, Bijsterveld NR, Moons AH, et al. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001; 104: 3063-8.
9. Endler G, Lalouschek W, Exner M, et al. The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol 2000; 110: 469-71.
10. Hindorff LA, Schwartz SM, Siscovick DS, et al. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 2002; 9: 131-7.
11. Hoekstra T, Geleijnse JM, Kluft C, et al. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke 2003; 34: 2822-8.
12. Roest M, van der Schouw YT, Banga JD, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000; 101: 67-70.
13. Bang CO, Park HK, Ahn MY, et al. 4G/5G polymorphism of the plasminogen activator inbibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis 2001; 11: 294-9.
14. Crainich P, Jenny NS, Tang Z, et al. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost 2003; 1: 1799-804.
15. Festa A, D'Agostino RA, Rich SS, et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, hispanics, and non-hispanic whites. Circulation 2003; 107: 2422-7.
16. Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-6.
17. Adams Jr. HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Stroke 1993; 24: 35-41.
18. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965; 14: 61-5.
19. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977; 74: 5463-7.
20. Falk G, Almqvist A, Nordenhem A. Allele specific PCR for detection of a sequence polymorphism in the promotor region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 1995; 9: 170-4.
21. Declerck PJ. Plasminogen activator inhibitor-1 (PAI-1) antigen. Laboratory techniques in thrombosis. A manual 2000; 239-45 ((?| Title of manual)).
22. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995; 74: 1032-4.
23. Ridker PM, Hennekens CH, Lindpaintner K, et al. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62.
24. Juhan-Vague I, Alessi M-C, Mavri A, et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-9.
25. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2004; 342: 1792-801.